The global hormone-sensitive advanced prostate cancer treatment market is expected to be worth US$12.44 Billion in 2023. According to Future Market Insights, the market will grow at a 7.2% CAGR until 2033, with a market value of US$ 24.94 Billion.
The primary goal of the key providers is translating science into innovative oncology medicines for helping people with cancer globally, where they commit to potentially bringing new hope driving the purpose, and supporting accessibility through their cancer medicines.
Recurrent/non-responsive prostate cancer is a major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to the recurrence or spread of cancer after initial treatment. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment.
Acquire a stunning sample report featuring compelling graphs and charts.
https://www.futuremarketinsights.com/reports/sample/rep-gb-17047
The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for the approval of new drugs and lays down regulations related to the treatment of prostate cancer. This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market.
The treatment landscape for patients with hormone-sensitive prostate cancer (HSPC) has changed dramatically in the past five years, despite little change in the preceding 20 years. Such rapid change can make it difficult for clinicians to remain abreast of the current literature and synthesize the relevant data to inform evidence-based treatment decisions.
A new treatment is approached for prostate cancer that could stop resistance in its tracks. North America is the largest region in the prostate cancer drugs market in 2022. The Middle East is expected to be the agile growing region in the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Key Takeaways from this Market Study:
- According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment.
- The global hormone-sensitive advanced prostate cancer treatment market grew at a CAGR of 6.6% from 2018 to 2022.
- According to ACL (Administration for Community Living), a US-based government organization, the geriatric population is expected to increase by 21.6% by 2040.
- As per the American Cancer Society, prostate cancer costs on average US$ 4,300 upfront and US$ 9,100 over five years, with surgery costing US$ 15,000 upfront and US$ 19,000 over five years.
Competitive Landscape:
Some of the prominent players in the global market for Hormone Sensitive Advanced Prostate Cancer Treatment Market are-
- Novartis Pharmaceuticals
- Merck & Co., Inc.
- Bristol-Myers
- Dendreon Corporation
- GlaxoSmithKline plc.
- Ferring International Center S.A.
- Roche Group
- Celgene Corporation
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
Buy Now and Gain Access to Identify Key Trends, Drivers, and Challenges in the Market
https://www.futuremarketinsights.com/checkout/17047
Some of the important developments of the key players in the market are:
- In March 2022, Novartis AG received USFDA approval for Pluvicto. It is the first targeted radioligand therapy in prostate cancer, which is a type of targeted cancer treatment that combines a targeting chemical (ligand) with a therapeutic radioisotope (a radioactive particle). Reimagining medication administered via intravenous infusion for the treatment of progressive, PSMA-positive metastatic castration-resistant metastatic prostate cancer by destroying tumor cells.
- In June 2021, Bayer acquired Noria and PSMA Therapeutics to fulfil patients’ clinical needs and broaden the metastatic prostate cancer treatment portfolio. Bayer’s oncology portfolio was expanded as a result of this acquisition, which included alpha radionuclide therapy and small molecules targeting Prostate-Specific Membrane Antigen (PSMA).
- In December 2020, Myovant Sciences and Pfizer announced a partnership to develop and commercialize a Relugolix combination tablet for advanced metastatic prostate cancer treatment. This groundbreaking partnership considerably enhances ORGOVYX’s (relugolix) launch, as well as the future introduction of relugolix combination tablets, and increases the pipeline of potential new medications.
More Valuable Insights Available:
Future Market Insights offers an unbiased analysis of the global Hormone Sensitive Advanced Prostate Cancer Treatment Market providing historical data for 2018-2022 and forecast statistics from 2023 to 2033.
To understand opportunities in hormone-sensitive advanced prostate cancer treatment, the market is segmented based on treatment (androgen ablation therapy, chemotherapy, targeted therapy, and cryotherapy), and end-user (hospitals, clinics, and cancer rehabilitation centers) across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa).
Key Segments Profiled:
By Treatment:
- Androgen Ablation Therapy
- Chemotherapy
- Targeted Therapy
- Cryotherapy
By End User:
- Hospitals
- Clinics
- Cancer Rehabilitation Centers
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
